a novel composite endpoint of toxicity and pfs in patients with r/r fl treated with axi-cel
Published 1 year ago • 83 plays • Length 3:33Download video MP4
Download video MP3
Similar videos
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:51
refract: standard chemoimmunotherapy versus novel agents in r/r follicular lymphoma
-
0:45
difference between quality of life & patient-reported outcomes
-
3:01
novel promising agents and clinical trials in amyloidosis
-
3:35
adding chemotherapy to immunotherapy in metastatic crc
-
28:08
dr. gaby hobbs, md: diagnosis and initial treatment options for et, pv & mf
-
26:46
webinar recording | technology advances in hematology testing | sparrc 2021 by srmc | mindray india
-
0:51
a novel adc, azd5335, for the treatment of solid tumors
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
4:13
benefit trial: isatuximab, lenalidomide, and dexamethasone /- bortezomib in newly diagnosed myeloma
-
1:51
checkpoint inhibition in the treatment of mpns
-
1:14
novel inducers of apoptosis in double-refractory cll cells
-
2:19
how cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
-
0:52
tocilizumab for aa amyloidosis
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
1:54
a novel clinical trial endpoint for acute gvhd
-
1:17
novel treatment approaches being explored in amyloidosis: immunotherapeutic agents & venetoclax
-
2:25
novel ai model for personalized risk stratification & treatment in newly diagnosed multiple myeloma
-
5:07
daratumumab in the management of al amyloidosis
-
0:55
a pooled analysis to determine the optimal ki-67 index cut-off point for predicting outcomes in mcl
-
2:41
an overview of the latest advances in hematology